Net Cash Provided by (Used in) Financing Activities in USD of Akebia Therapeutics, Inc. from 2016 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Akebia Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to Q1 2025.
  • Akebia Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $74.9M, a 306% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $49.7M.
  • Akebia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$25.2M, a 273% decline from 2022.
  • Akebia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $14.6M, a 89.1% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Akebia Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $74.9M +$56.5M +306% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q1 2024 $18.5M +$34.4M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q1 2023 -$16M -$63.5M -134% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $47.5M -$26.9M -36.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 $74.5M +$17.1M +29.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $57.3M +$71.8M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q1 2019 -$14.4M -$110M -115% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q1 2018 $95.9M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09

Akebia Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $49.7M +$74.9M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 -$25.2M -$39.8M -273% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 $14.6M -$119M -89.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $134M -$98M -42.3% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-08-28
2020 $232M +$143M +160% Jan 1, 2020 Dec 31, 2020 10-K/A 2023-08-28
2019 $89M -$7.59M -7.86% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $96.6M -$19.7M -16.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $116M +$49.3M +73.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $66.9M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.